The Ashitaba ( <i>Angelica keiskei</i> ) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K
Tianshun Zhang(Hong Kong Polytechnic University), Zigang Dong(China-US (Henan) Hormel Cancer Institute), Mee‐Hyun Lee(Dongshin University), Naomi Oi(University of Minnesota), Xiaoyu Chang, Mangaladoss Fredimoses(Chinese Academy of Sciences), Ann M. Bode(University of Minnesota), Ge Gao(Affiliated Hospital of Jining Medical University), Scott M. Lippman(UC San Diego Health System), Hitoshi Ashida(Kobe University), Qiushi Wang(Hormel (United States)), Ting Wang(Jilin University), Keke Wang(Shanxi Medical University), Tatyana A. Zykova(Hormel (United States)), Ke Yao(Hormel (United States)), Kanamata Reddy(University of Minnesota), Hanyong Chen(University of Minnesota Medical Center), Weiya Ma(University of Minnesota), Moeez Rathore(Case Western Reserve University)
Cited by 15
Related Papers
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|726
Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
|Cell Metabolism|2018|420
Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells.
|Proceedings of the National Academy of Sciences|1994|390